Original Research
Accepted on 26 Sep 2023
ADALIMUMAB BIOSIMILAR ABP 501 IS EQUALLY EFFECTIVE AND SAFE IN LONG-TERM MANAGEMENT OF INFLAMMATORY BOWEL DISEASES PATIENTS WHEN USED AS FIRST BIOLOGIC TREATMENT OR AS REPLACE OF THE ADA ORIGINATOR FOR A NON-MEDICAL REASON
in Therapy in Gastroenterology